Send us Fan Mail

A small ASX biotech can feel impossible to value until the data starts landing, and that’s exactly where Syntara is headed. We’re joined by CEO Gary Phillips to map out a tight run of clinical catalysts and the thinking behind a pipeline built around extracellular matrix dysfunction and amine oxidase chemistry, backed by specialist institutional investors and real in-house drug discovery.

We dig into Amsulostat, the lead program in myelofibrosis, and what positive FDA feedback actually means in practice: a clearer regulatory development pathway, a Phase 2B add-on design against placebo alongside JAK inhibitor standard of care, and stronger footing for potential partnering conversations in hematology and oncology. Gary also explains why safety and symptom score improvements matter so much at this stage, especially in diseases where current options can be hard to tolerate.

From there we switch gears into two more high-interest areas. In myelodysplastic syndrome (MDS), we cover the unmet need, the significance of grant-backed trials in Germany and Australia, and why indication expansion can materially lift an asset’s commercial upside. We also explore SNT 4728 in isolated REM sleep behavior disorder (IRBD), a sleep condition that can precede Parkinson’s disease, and how a placebo-controlled study funded by Parkinson’s UK uses brain imaging to look for reduced inflammation. Finally, we talk skin scarring, including hypertrophic and keloid scars, why function and mental health outcomes matter, and what a once-daily topical approach could mean if results stack up.

If you follow ASX biotech, clinical trials, FDA pathways, or early signals in Parkinson’s research, this chat is built for your watchlist. Subscribe, share the episode with a mate who tracks biotech's, and leave us a review so more people can find the show.